Pfizer's Dividend Yield Is 10X Bigger Than Eli Lilly's: Does That Make It the Better Income Stock?
Pfizer's dividend yield stands at approximately 5.8%, ten times higher than Eli Lilly's 0.6%. However, Pfizer faces operational headwinds, while Eli Lilly enjoys strong growth.
Key Numbers
According to a report from Motley Fool, a comparative analysis between pharmaceutical giants Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) reveals a significant gap in dividend yields. While Pfizer offers a yield of approximately 5.8%, Eli Lilly's yield is only about 0.6%, making Pfizer's yield ten times larger.
Recommendation Change
No change in analyst recommendations was reported; this is a comparative analysis highlighting the yield difference.
Analyst Rationale
Analysts note that Pfizer offers an attractive yield for income investors but faces headwinds from declining COVID-19 product sales and patent expirations on key drugs. In contrast, Eli Lilly is experiencing strong growth driven by new drugs like Mounjaro and Zepbound, reducing its need for high dividend payouts.
Context
Pfizer's stock has underperformed recently, while Eli Lilly's shares have risen significantly. Other analysts recommend Pfizer as a value opportunity, while focusing on growth for Eli Lilly.
Conclusion
The choice depends on investor goals: for steady income, Pfizer may be suitable despite risks; for capital appreciation, Eli Lilly might be preferable.
Frequently Asked Questions
Found this useful? Share it